Results 171 to 180 of about 89,579 (296)

Controlled Release of Human Dental Pulp Stem Cell‐Derived Exosomes from Hydrogels Attenuates Temporomandibular Joint Osteoarthritis

open access: yesAdvanced Healthcare Materials, EarlyView.
Exosomes can reduce tissue damage in temporomandibular joint osteoarthritis (TMJOA), but rapid clearance limits their efficacy. This study encapsulates exosomes in hyaluronic acid hydrogels for controlled release. In a rat model, hydrogel‐encapsulated exosomes outperform free exosomes in preserving bone integrity and reducing tissue destruction ...
Victor Diez‐Guardia   +7 more
wiley   +1 more source

Lipid Nanoparticle‐Mediated CRISPR‐Cas13a Delivery for the Control of Bacterial Infection

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
New formulations of lipid nanoparticles (LNPs) that can deliver nucleic acids to Gram‐negative bacteria are proposed to combat bacterial infection. The delivery of nucleic acids by LNPs is aided by LNP‐helpers which weaken the bacterial outer membrane. LNPs encapsulating the Cas13a/gRNA expression vector achieve an antibacterial effect in both in vivo ...
Bookun Kim   +9 more
wiley   +1 more source

Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Islatravir‐loaded dissolving microarray patches (MAPs) provide a minimally invasive, long‐acting solution for HIV‐1 prevention and treatment. In rats, sustained islatravir delivery lasts up to three months, while in minipigs, efficacious plasma levels are detected for six days.
Qonita Kurnia Anjani   +11 more
wiley   +1 more source

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li   +9 more
wiley   +1 more source

Studies on Analysis of Mixed Anti-cold Pharmaceutical Preparations. III

open access: bronze, 1965
Shin‐ichi Ono   +3 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy